Trial Profile
A Randomized, Double-blind, Placebo-controlled First Time Into Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intranasal Dosing With GSK2245035, a TLR7 Agonist, in Healthy Volunteers and Allergic Rhinitics.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Dec 2023
Price :
$35
*
At a glance
- Drugs GSK 2245035 (Primary)
- Indications Seasonal allergic rhinitis
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Sponsors GSK
- 30 Nov 2011 New trial record